Brian Tse
Positions
- Postdoctoral Research Fellow, APCRC-Q
- Member, IHBI, QUT
Qualifications
- PhD, University of New South Wales, Australia, 2011
- DipInnovMan, University of New South Wales, Australia, 2006
- BMedSc (Hon), University of New South Wales, Australia, 2005
Biography
Dr Brian Tse is an early career researcher who was awarded his PhD from the University of New South Wales, Sydney, in 2011, for his work on developing novel forms of immunotherapy for prostate cancer. He then held a two-year post-doctoral position at the Lowy Cancer Research Centre, Sydney, studying the role of glycosylation and anti-glycan immunoglobulins in ovarian cancer biology.
Dr Tse joined the APCRC-Q in August 2012, and has been working on a number of projects:
- Multimodal hyperbranched polymers for simultaneous imaging and drug delivery for prostate cancer theranostics,
- Developing a novel therapeutic strategy targeting KLK4 to inhibit prostate cancer growth and metastasis,
- Elucidating the molecular drivers of prostate cancer metastasis and progression to castrate-resistant disease, and
- Prostate cancer immunotherapy.
He was recently awarded a prestigious two-year United States Department of Defence (DOD) Postdoctoral Training Award for Prostate Cancer Research (Fellowship).
Awards and grants
Awards
|
2014-2016 |
United States Department of Defence (DOD) Prostate Cancer Postdoctoral Training Award (Fellowship) - Developing a novel therapeutic strategy targeting KLK4 to inhibit prostate cancer growth and metastasis. |
|
2007-2009 |
Australian Rotary Health PhD scholarship for Prostate Cancer Research |
|
2006 |
Prince of Wales Clinical School Postgraduate Research Scholarship |
|
2005 |
Tow Prize (Junior Division) |
|
2004 |
Juvenile Diabetes Research Foundation Summer Scholarship |
Research interests
Theranostics, cancer imaging, nanobiotechnology, epithelial-mesenchymal plasticity, apoptosis, tumour immunology.
Top publications
- Russell PJ, Russell P, Rudduck C, Tse BW-C, Williams ED. Raghavan D. Establishing prostate cancer patient derived xenografts: lessons learned from older studies. The Prostate. 2015 Jan 5. doi: 10.1002/pros.22946. (JIF:3.57)
- Tse BW-C, Cowin G, Soekmadji C, Jovanovic L, Vasireddy RS, Ling M-T, Khatri A, Liu TQ, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine. 2014. doi: 10.2217/NNM.14.122. (JIF:5.82)
- Pearce AK, Rolfe B, Russell PJ, Tse BW-C, Whittaker AK, Fuchs AV, Thurecht KJ. Development of a polymer theranostic for prostate cancer.Polymer Chemistry. 2014. doi:10.1039/C4PY00999A. (JIF:5.37)
- Tse BW-C, Collins A, Oehler MK, Collins A, Zipplelius A, Heinzelmann-Schwarz V. Antibody-based immunotherapy for ovarian cancer – where are we at?Annals of Oncology. 2014, (25):322-331. (JIF:6.58)
- Tse BW-C, Russell PJ, Lochner M, Forster I, Power CA. IL-18 Inhibits Growth of Murine Orthotopic Prostate Carcinomas via Both Adaptive and Innate Immune Mechanisms.PLoS ONE. 2011; 6(9):e24241. doi:10.1371/journal.pone.0024241. (JIF:3.56)
More publications are available on Google Scholar
Professional memberships and associations
|
2012 |
American Association for Cancer Research (AACR) |
|
2010-now |
Australia Society for Medical Research (ASMR) |
|
2009-now |
Australian Society for Immunology (ASI) |
